Abnormal expression of MIR31HG has been reported in a diverse range of cancer types, including osteosarcoma [15], chordoma [16], colorectal cancer (CRC) [17–19], hepatocellular carcinoma (HCC) [6], lung cancer [2, 20–24], gastric cancer [25], bladder cancer [26], pancreatic ductal adenocarcinoma (PDAC) [7], oral squamous cell carcinoma (OSCC) [4], breast cancer [13, 27], cervical cancer [28], vulvar squamous cell carcinoma (VSCC) [29], and esophageal squamous cell carcinoma (ESCC) [30, 31]. This evidence concerns the gene MIR31HG and urinary bladder carcinoma.